HER2阳性乳腺癌的免疫治疗：一项系统综述。
Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review.
作者信息
Kyriazoglou Anastasios, Kaparelou Maria, Goumas Georgios, Liontos Michael, Zakopoulou Roubini, Zografos Eleni, Zygogianni Anna, Dimopoulos Meletios Athanasios, Zagouri Flora
机构信息
Department of Clinical Therapeutics, General Hospital Alexandra, Athens, Greece.
Department of Medical Oncology, Aghios Savvas Anticancer Hospital, Athens, Greece.
出版信息
Breast Care (Basel). 2022 Feb;17(1):63-70. doi: 10.1159/000514860. Epub 2021 Mar 29.
Abstract
INTRODUCTION
The clinical outcome of HER2-positive breast cancer patients changed with the use of anti-Her therapies, though it still remains an aggressive and fatal disease. Implementation of immune checkpoint inhibitors in HER2-positive Breast cancer is a concept supported by the reported biological and preclinical data.
METHODS
We conducted a systematic review of the current literature involving immune checkpoint inhibitors alone or in combination with targeted therapies or chemotherapy finalized or running in HER2-positive breast cancer.
RESULTS
Twelve clinical trials and 2 case reports were identified in our study.
CONCLUSION
The reported clinical trials highlight that checkpoint inhibition seems to be promising in metastatic, neoadjuvant, and adjuvant settings of HER2-positive breast cancer.
摘要
引言
尽管HER2阳性乳腺癌患者使用抗HER疗法后临床结局有所改变，但它仍是一种侵袭性致命疾病。在HER2阳性乳腺癌中应用免疫检查点抑制剂这一概念得到了已报道的生物学和临床前数据的支持。
方法
我们对目前涉及免疫检查点抑制剂单独使用或与靶向治疗或化疗联合使用、已完成或正在进行的HER2阳性乳腺癌相关文献进行了系统综述。
结果
我们的研究中确定了12项临床试验和2例病例报告。
结论
已报道的临床试验表明，在HER2阳性乳腺癌的转移、新辅助和辅助治疗中，检查点抑制似乎很有前景。
相似文献
1
Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review.HER2阳性乳腺癌的免疫治疗：一项系统综述。
Breast Care (Basel). 2022 Feb;17(1):63-70. doi: 10.1159/000514860. Epub 2021 Mar 29.
2
Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer.HER2靶向药物与免疫检查点抑制剂联合治疗HER2阳性乳腺癌
Expert Opin Biol Ther. 2022 Mar;22(3):385-395. doi: 10.1080/14712598.2021.1981284. Epub 2021 Nov 21.
3
Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer.早期HER2阳性乳腺癌的围手术期HER2靶向治疗。
Ther Adv Med Oncol. 2022 Jun 21;14:17588359221106564. doi: 10.1177/17588359221106564. eCollection 2022.
4
Neoadjuvant Therapy for HER2-positive Breast Cancer.HER2阳性乳腺癌的新辅助治疗
Rev Recent Clin Trials. 2017;12(2):81-92. doi: 10.2174/1574887112666170202165049.
5
Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.早期三阴性乳腺癌免疫检查点抑制的进展
Expert Rev Anticancer Ther. 2023 Jul-Dec;23(10):1071-1084. doi: 10.1080/14737140.2023.2262764. Epub 2023 Oct 26.
6
Immunotherapy as a partner for HER2-directed therapies.免疫疗法作为曲妥珠单抗治疗的伙伴。
Expert Rev Anticancer Ther. 2021 Jul;21(7):739-746. doi: 10.1080/14737140.2021.1894932. Epub 2021 Mar 9.
7
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.绝经后激素受体阳性、HER2 阴性转移性乳腺癌患者的内分泌治疗与化疗：系统评价和网络荟萃分析。
Lancet Oncol. 2019 Oct;20(10):1360-1369. doi: 10.1016/S1470-2045(19)30420-6. Epub 2019 Sep 4.
8
A systematic review of dual targeting in HER2-positive breast cancer.HER2 阳性乳腺癌的双重靶向治疗系统评价。
Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11.
9
Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer.临床试验数据与新兴免疫治疗策略：激素受体阳性、人表皮生长因子受体2阴性乳腺癌
Breast Cancer Res Treat. 2021 Aug;189(1):1-13. doi: 10.1007/s10549-021-06291-8. Epub 2021 Jul 2.
10
Trastuzumab-containing regimens for metastatic breast cancer.用于转移性乳腺癌的含曲妥珠单抗方案。
Cochrane Database Syst Rev. 2014 Jun 12;2014(6):CD006242. doi: 10.1002/14651858.CD006242.pub2.
引用本文的文献
1
Personalized treatment approach for HER2-positive metastatic breast cancer.针对人表皮生长因子受体 2（HER2）阳性转移性乳腺癌的个体化治疗方法。
Med Oncol. 2024 Sep 25;41(11):252. doi: 10.1007/s12032-024-02504-4.
2
The Role of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapies in Early-Stage Breast Cancer: Current Practices, Treatment De-escalation, and Future Prospects.人表皮生长因子受体2（HER2）靶向治疗在早期乳腺癌中的作用：当前实践、治疗降阶梯及未来前景
Cureus. 2024 Feb 29;16(2):e55230. doi: 10.7759/cureus.55230. eCollection 2024 Feb.
3
Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer-A Literature Review.早期HER2阳性乳腺癌全身治疗策略评估——文献综述
Cancers (Basel). 2023 Aug 30;15(17):4336. doi: 10.3390/cancers15174336.
4
Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs.克服抗HER2靶向药物耐药性的新型疗法与策略
Cancers (Basel). 2022 Sep 19;14(18):4543. doi: 10.3390/cancers14184543.
5
Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer.程序性死亡配体1（PD-L1）作为乳腺癌免疫治疗生物标志物
Cancers (Basel). 2022 Jan 8;14(2):307. doi: 10.3390/cancers14020307.
本文引用的文献
1
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.早期三阴性乳腺癌患者新辅助阿替利珠单抗联合序贯纳武利尤单抗和基于蒽环类的化疗与安慰剂和化疗相比：一项随机、双盲、III 期试验（IMpassion031）。
Lancet. 2020 Oct 10;396(10257):1090-1100. doi: 10.1016/S0140-6736(20)31953-X. Epub 2020 Sep 20.
2
A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).一项评估度伐利尤单抗联合曲妥珠单抗治疗 HER2 阳性转移性乳腺癌（CCTG IND.229）的 Ib 期临床试验。
Oncologist. 2019 Nov;24(11):1439-1445. doi: 10.1634/theoncologist.2019-0321. Epub 2019 Aug 16.
3
The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine.欧洲肿瘤内科学会早期乳腺癌临床实践指南：诊断、治疗与随访：通往个性化医疗的曲折之路
Ann Oncol. 2019 Aug 1;30(8):1183-1184. doi: 10.1093/annonc/mdz201.
4
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.帕博利珠单抗联合曲妥珠单抗治疗曲妥珠单抗耐药的晚期 HER2 阳性乳腺癌（PANACEA）：一项单臂、多中心、Ib-2 期试验。
Lancet Oncol. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11.
5
Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.HER2阳性乳腺癌的免疫治疗：最新进展与联合治疗方法
Breast Cancer (Dove Med Press). 2019 Jan 17;11:53-69. doi: 10.2147/BCTT.S175360. eCollection 2019.
6
ASCO 2018: highlights in HER2-positive metastatic breast cancer.美国临床肿瘤学会2018年会议：HER2阳性转移性乳腺癌研究亮点
Memo. 2018;11(4):280-283. doi: 10.1007/s12254-018-0441-x. Epub 2018 Oct 11.
7
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌。
N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.
8
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.软组织和内脏肉瘤：ESMO-EURACAN诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269. doi: 10.1093/annonc/mdy321.
9
Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer.HER2阳性难治性转移性乳腺癌患者肿瘤突变负荷的临床意义
Oncoimmunology. 2018 May 24;7(8):e1466768. doi: 10.1080/2162402X.2018.1466768. eCollection 2018.
10
Is there a role for immunotherapy in HER2-positive breast cancer?免疫疗法在HER2阳性乳腺癌中是否有作用？
NPJ Breast Cancer. 2018 Aug 15;4:21. doi: 10.1038/s41523-018-0072-8. eCollection 2018.
Zotero 插件